Navigation Links
More than 2,000 People Climb to Top of Chicago's Sears Tower
Date:11/9/2008

Sears Tower raises close to $400,000 for the Damon Runyon Cancer Research

Foundation

CHICAGO, Nov. 9 /PRNewswire/ -- Go Vertical Chicago, the annual charitable stair climb to the top of the Sears Tower, today raised close to $400,000 for young scientists funded by the Damon Runyon Cancer Research Foundation (http://www.damonrunyon.org). Now in its seventh year, the climb to the top of one of the world's tallest buildings attracted 2,000 people, who ascended 2,109 steps to the 103rd floor, home of the famous Sears Tower Skydeck.

Climbers from as far away as Germany and Italy were joined by Chicago locals, their families and supporters. Terry Purcell, 37, won the male and overall prize, with a time of 13:55. Cindy Harris, 39, won the female division for the seventh straight year in a time 15:45. The record time is 13:26 minutes, set in 2005.

One hundred percent of the donations from the stair climb go to young cancer researchers funded by the Damon Runyon Cancer Research Foundation.

"It's both inspirational and humbling to see people of all ages and abilities climbing for cancer research," said Lorraine Egan, executive director, Damon Runyon Cancer Research Foundation. "We're very grateful for the support of all our participants and sponsors and thank them for helping to make this year's Go Vertical Chicago a fantastic event."

Many participants are cancer survivors, while others climbed for friends and loved ones. The youngest climber was 7 years old and the oldest 80 years old.

Randy Stancik, vice president, U.S. Equities Asset Management, Sears Tower's leasing and management agent, said: "We're proud to have hosted the climb to the top of one of the world's most iconic buildings. The Sears Tower is the standard for tall buildings, and this Sunday, we're happy to have raised money for cancer research and help thousands of athletes se
'/>"/>

SOURCE Damon Runyon Cancer Research Foundation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Sigma-Aldrich and Atlas Antibodies Announce the Release of 2,000 New, Highly-Validated Prestige Antibodies
2. 2008 Give Kids A Smile! Involves More Than 12,000 North Carolina Children
3. 4-Star Gen. Barry McCaffrey, Former U.S. Drug Czar, and Dr. Barry Karlin, Nations #1 Drug Treatment Provider, to Spearhead Drug Treatment WVA Advocacy Day Feb 13-14; 142,000 Need, Dont Get Treatment in State
4. TriWest Contributes $12,000 to Alaska National Guard Fund
5. Families Face Harsh Reality: 2,000 Children Join the Uninsured Each Day
6. Statin Might Help More People Fight Heart Disease Than Thought
7. 5,000 People Expected to March to End Homelessness in Los Angeles County
8. 50,000 Young People Dance to Celebrate Achievements in Pushing Back HIV and AIDS
9. More People Living Longer After Cancer Diagnosis
10. National Multiple Sclerosis Society New Jersey Metro Chapter Looking for People to Join the Movement
11. Keppra XR(TM) Offers Convenient Dosing For People With Partial Onset Seizures
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 2For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 3Genoptix Announces Participation at Deutsche Bank 2009 MedTools Investor Conference 2Merieux Alliance Becomes Institut Merieux 2Merieux Alliance Becomes Institut Merieux 3Merieux Alliance Becomes Institut Merieux 4Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 57565 1Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 57565 2Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 57565 3Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 57565 4Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 57565 5Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 57565 6Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 57565 7TCT 2009 to Feature vProtect 28TM 29 Luminal Shield a Novel Treatment Designed for Soft Coronary Lesions from Prescient Medical 14134 1TCT 2009 to Feature vProtect 28TM 29 Luminal Shield a Novel Treatment Designed for Soft Coronary Lesions from Prescient Medical 14134 2Photo 3A Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 14132 1Photo 3A Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 14132 2Photo 3A Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 14132 3Photo 3A Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 14132 4Photo 3A Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 14132 5Photo 3A Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 14132 6Photo 3A Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 14132 7